- Home
- LSAK vs ZBIO Comparison
LSAK vs ZBIO Comparison
Compare LSAK & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- ZBIO
- Stock Information
- Founded
- LSAK 1997
- ZBIO 2019
- Country
- LSAK South Africa
- ZBIO United States
- Employees
- LSAK N/A
- ZBIO N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- ZBIO
- Sector
- LSAK Finance
- ZBIO
- Exchange
- LSAK Nasdaq
- ZBIO NYSE
- Market Cap
- LSAK 344.5M
- ZBIO 389.2M
- IPO Year
- LSAK N/A
- ZBIO 2024
- Fundamental
- Price
- LSAK $4.43
- ZBIO $9.65
- Analyst Decision
- LSAK
- ZBIO Strong Buy
- Analyst Count
- LSAK 0
- ZBIO 7
- Target Price
- LSAK N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- LSAK 28.4K
- ZBIO 217.6K
- Earning Date
- LSAK 05-07-2025
- ZBIO 08-16-2025
- Dividend Yield
- LSAK N/A
- ZBIO N/A
- EPS Growth
- LSAK N/A
- ZBIO N/A
- EPS
- LSAK N/A
- ZBIO N/A
- Revenue
- LSAK $574,080,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- LSAK $1.06
- ZBIO $206.00
- Revenue Next Year
- LSAK $13.32
- ZBIO $41.92
- P/E Ratio
- LSAK N/A
- ZBIO N/A
- Revenue Growth
- LSAK 4.13
- ZBIO N/A
- 52 Week Low
- LSAK $3.39
- ZBIO $5.83
- 52 Week High
- LSAK $5.60
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- LSAK 59.14
- ZBIO N/A
- Support Level
- LSAK $3.85
- ZBIO N/A
- Resistance Level
- LSAK $4.24
- ZBIO N/A
- Average True Range (ATR)
- LSAK 0.24
- ZBIO 0.00
- MACD
- LSAK 0.03
- ZBIO 0.00
- Stochastic Oscillator
- LSAK 74.42
- ZBIO 0.00
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.